Macrogenics down 14% premarket on doubts with margetuximab data

Oct. 23, 2019 8:38 AM ETMacroGenics, Inc. (MGNX)MGNXBy: Douglas W. House, SA News Editor
  • Macrogenics (NASDAQ:MGNX) slips 14% premarket, albeit on only 620 shares, on the heels of updated survival data from a Phase 3 clinical trial evaluating margetuximab in patients with HER2-positive breast cancer.
  • The combination of the HER2-targeting monoclonal antibody and chemo showed a median increase in overall survival (OS) of 1.8 months (21.6 months vs. 19.8 months) compared to the combination of Roche's Herceptin + chemo with 11.5% less risk of death (hazard ratio = 0.885). The confidence interval for the hazard ratio, however, was 0.693 - 1.130 with a p value of 0.326, meaning, basically, that treatment with margetuximab may not have improved survival at all.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.